Correlations of the Complement Proteins MASP‐2 and MASP‐3 With Clinical Severity and Short‐Term Outcomes in Primary Membranous Nephropathy Patients

Documenti analoghi

• The Optimal Management Strategy for IGA Nephropathy Patients With Different Clinical Presentations
  di: Savas Ozturk, et al.
  Pubblicazione: (2026)
• Economic Evaluation of Rituximab Versus Corticosteroid‐Cyclophosphamide or Cyclosporine in Patients With Membranous Nephropathy in Republic of Korea
  di: Heejung Choi, et al.
  Pubblicazione: (2025)
• Correspondence on “New Onset of Primary Membranous Nephropathy After COVID ‐19 mRNA Vaccination in Affected Sjogren's Syndrome”
  di: Hinpetch Daungsupawong, et al.
  Pubblicazione: (2025)
• Effectiveness of Semaglutide in Overweight or Obese Patients With IgA Nephropathy Without Diabetes
  di: Feng‐Lei Si, et al.
  Pubblicazione: (2025)
• A Mendelian Randomization Study on the Association Between Sex Hormone‐Binding Globulin and Membranous Nephropathy Risk
  di: Yingxin Fang, et al.
  Pubblicazione: (2025)